AC Immune SA is a clinical stage biopharmaceutical company. It discovers, designs and develops novel, proprietary medicines for treatment of neurodegenerative diseases with the help of proprietary platforms.
Stock Price Prediction
Update at 5:00pm EST
9.414 - 9.477
9.477 - 9.53
8.388 - 8.445
8.445 - 8.492
8.556 - 8.649
8.649 - 8.727
as of: 2020-01-24 4:29:19 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.ACIU has closed above bottom band by 1.1%. Bollinger Bands are 7.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
2019-11-05 AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy? AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2019-09-23 AC Immune to Earn Milestone From Lilly for Alzheimer's Drug AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.